LISCure Biosciences Inc.

1:45 PM - 2:00 PM (PDT), Tuesday, June 14, 2022
LISCure Biosciences is developing 'bacteria-based cancer immunotherapy' and 'microbiome therapy' for major therapeutic areas such as oncology, liver diseases, autoimmune diseases, and neuroscience. LISCure’s approach to therapeutics is developing different single bacterial strains for each pipeline.
LISCure’s proprietary candidate for ‘bacteria-based cancer immunotherapy (injection)’ is in the pre-IND stage and is being developed with a new modality of non-pathogenic bacteria. For ‘microbiome therapy (oral)’, LISCure has two (2) microbiome programs for liver diseases and autoimmune diseases in the clinical stage, and one (1) candidate for neuroscience in the IND-enabling stage.
LISCure Microbiology-based Technology (“LMT”) Platform ensures the sustainability in the discovery of new drug candidates and success in clinical trials. LMT Platform is comprised of the integrated and seamless processes of three pillars: therapeutic screening, microbial optimization, and microbiome database.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
LB-P8 for liver diseases and LB-P2D for cancers
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Director of Business Development
LISCure Biosciences